Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
04:05pm, Tuesday, 10'th Feb 2026
SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results o
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth
11:00am, Tuesday, 10'th Feb 2026
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock
04:44am, Saturday, 07'th Feb 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold a
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 04'th Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
11:43pm, Monday, 02'nd Feb 2026
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 02'nd Feb 2026
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:50am, Friday, 30'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s
01:37am, Friday, 30'th Jan 2026
Halozyme Therapeutics (NASDAQ: HALO) used an investor conference call to outline a series of strategic and financial updates, highlighting what CEO Dr. Helen Torley described as an unusually concentra
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
12:55pm, Thursday, 29'th Jan 2026
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO
04:24am, Thursday, 29'th Jan 2026
Federated Hermes Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 294.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exch
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript
12:12pm, Wednesday, 28'th Jan 2026
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
06:30am, Wednesday, 28'th Jan 2026
Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Fi
Hussman Strategic Advisors Inc. Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO
05:52am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 62.5% during the undefined quarter, according to its most recent filing with the Secur
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
02:00pm, Saturday, 24'th Jan 2026
Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Moderate Buy” by Brokerages
02:48am, Friday, 23'rd Jan 2026
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen research firms that are presently covering the stock
